Key result
The experimental TASK-1 inhibitor A293, while potentially effective for atrial fibrillation, may induce pulmonary arterial hypertension and right ventricular dysfunction, requiring close monitoring.
Why the study?
Does the experimental TASK-1 potassium channel inhibitor A293 improve rhythm control in a translational large animal model of persistent atrial fibrillation?
Does the experimental TASK-1 potassium channel inhibitor A293 improve rhythm control in a translational large animal model of persistent atrial fibrillation?
The experimental TASK-1 potassium channel inhibitor A293 may be a viable strategy for rhythm control in persistent atrial fibrillation based on large animal model data.
Answers are grounded in this paper and cite their sources.
A293 supports rhythm control in a large-animal persistent AF model; leaves open translation to human disease.
Citation: Le Ribeuz H, Montani D and Antigny F (2021) The Experimental TASK-1 Potassium Channel Inhibitor A293 Can Be Employed for Rhythm Control of Persistent Atrial Fibrillation in a Translational Large Animal Model. Front. Physiol. 12:668267. doi: 10.3389/fphys.2021.668267 The Experimental TASK-1 Potassium Channel Inhibitor A293 Can Be Employed for Rhythm Control of Persistent Atrial Fibrillation in a Translational Large Animal Model
No takes yet. Share an insight, caveat, or question.
Ribeuz et al. (2021) conducted an editorial in Atrial fibrillation and pulmonary arterial hypertension. A293 (TASK-1 inhibitor) was evaluated. The experimental TASK-1 inhibitor A293, while potentially effective for atrial fibrillation, may induce pulmonary arterial hypertension and right ventricular dysfunction, requiring close monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: